Inflammatory myofibroblastic tumor (IMT), a tumor of myofibroblastic spindle cells accompanied by a lymphoplasmacytic and eosinophilic inflammatory infiltrate, and anaplastic large cell lymphoma share clonal aberrations involving the short arm of chromosome 2 in region p21-p23 (1-5). Chromosome 2p23 is the site of the human ALK gene, which codes for anaplastic lymphoma kinase, a tyrosine kinase receptor and member of the insulin growth factor receptor superfamily. Antibodies to the protein product of the ALK gene detect both ALK expression associated with 2p23 rearrangements and other abnormalities in ALK deregulation. ALK rearrangements and/or ALK1 and p80 immunoreactivity have been reported in 36 -60% of IMTs and 8 -33% of "inflammatory pseudotumors" (3, 5, 6 -9). Fusion oncogenes have been identified in a small proportion of IMTs with ALK rearrangements and include TPM3-ALK and TPM4-ALK (4). In anaplastic large cell lymphoma, the clonal abnormalities of ALK include a characteristic translocation t(2, 5)(p23;q35), variant translocations, and a TPM3-ALK fusion oncogene in some cases (2, 10 -15). Various investigators have shown that ALK gene rearrangements and ALK expression are found
Inflammatory myofibroblastic tumor (IMT), a tumor of myofibroblastic spindle cells accompanied by a lymphoplasmacytic and eosinophilic inflammatory infiltrate, and anaplastic large cell lymphoma share clonal aberrations involving the short arm of chromosome 2 in region p21-p23 (1) (2) (3) (4) (5) . Chromosome 2p23 is the site of the human ALK gene, which codes for anaplastic lymphoma kinase, a tyrosine kinase receptor and member of the insulin growth factor receptor superfamily. Antibodies to the protein product of the ALK gene detect both ALK expression associated with 2p23 rearrangements and other abnormalities in ALK deregulation.
ALK rearrangements and/or ALK1 and p80 immunoreactivity have been reported in 36 -60% of IMTs and 8 -33% of "inflammatory pseudotumors" (3, 5, 6 -9) . Fusion oncogenes have been identified in a small proportion of IMTs with ALK rearrangements and include TPM3-ALK and TPM4-ALK (4) . In anaplastic large cell lymphoma, the clonal abnormalities of ALK include a characteristic translocation t(2, 5)(p23;q35), variant translocations, and a TPM3-ALK fusion oncogene in some cases (2, 10 -15) . Various investigators have shown that ALK gene rearrangements and ALK expression are found in cell lines of neuroblastoma, neuroectodermal tumors, malignant melanoma, small cell lung carcinoma, and rhabdomyosarcoma and in central nervous system tissue (12, 15) . Thus, it appears that structural or functional abnormalities of the ALK gene are found in a group of mesenchymal neoplasms including anaplastic large cell lymphoma, IMT, and possibly others.
The purpose of this study is to systematically investigate by immunohistochemical means, with selective fluorescence in situ hybridization (FISH) analysis, whether the ALK family of tumors, whose current members are IMT and anaplastic large cell lymphoma, also includes mesenchymal tumors with a predominantly spindle cell phenotype and rhabdomyosarcoma.
MATERIALS AND METHODS

Case Selection
Formalin-fixed, paraffin-embedded archival tissue was obtained from institutional and consultation files. Cases included 10 IMTs and 125 small round blue cell and spindle cell tumors. These included 31 rhabdomyosarcomas, 10 nodular fasciitides, 10 desmoid-type fibromatoses, 10 infantile myofibromatoses, 10 infantile fibrosarcomas, 11 malignant fibrous histiocytomas, 10 synovial sarcomas, 10 malignant peripheral nerve sheath tumors, 3 myofibrosarcomas, 10 leiomyomas, and 10 leiomyosarcomas. The rhabdomyosarcomas included 16 alveolar and 15 embryonal (including 2 anaplastic, 1 spindle cell, and 2 botyroid) types. Soft tissue tumors were classified according to the World Health Organization Classification of Soft Tissue Tumors (16) , the International Classification of Rhabdomyosarcoma (17) , and published descriptions for myofibrosarcoma (18 -20) . Clinicopathologic and immunohistochemical findings for some cases of IMT, rhabdomyosarcoma, and infantile fibrosarcoma had been previously published (1, 3, 8, (21) (22) (23) . Five of 10 IMTs were included in a previous study of ALK-1 and p80 expression and chromosome 2p23 rearrangements (5), and 8 were included in a separate study (8) . All specimens were originally diagnosed between 1976 and 2000. All of the inflammatory myofibroblastic tumors, rhabdomyosarcoma, infantile myofibromatoses, infantile fibrosarcomas, and myofibrosarcomas were from children and adolescents. All of the leiomyomas were from adults. The remaining tumors occurred in both children and adults. The original surgical pathology reports were reviewed, and the diagnoses were confirmed by review of hematoxylin and eosin-stained sections and immunohistochemical studies. One representative block for each case was selected for immunohistochemical staining.
Antibodies and Immunostaining
Immunohistochemical studies were performed on 4-m-thick formalin-fixed, paraffin-embedded tissue sections, using a standard heat-induced epitope retrieval method, a standard avidin-biotin peroxidase complex detection technique, and an automated immunostainer (Ventana Medical Systems, Tucson, AZ).
The monoclonal ALK1 antibody was obtained from DAKO Company (Carpinteria, CA). ALK1 staining was done after heat-induced epitope retrieval in an electric pressure cooker for 3 minutes (total time in pressure cooker, 30 min) in a citrate buffer at pH 6.0. The antibody was applied at a dilution of 1:25 for 32 minutes using the Ventana Nexus autostainer with a basic diaminobenzidine detection kit, endogenous peroxidase blocking, and staining amplification kit.
The polyclonal p80 NPM/ALK antibody was obtained from Monosan (Leiden, the Netherlands). p80 staining was done after heat-induced epitope retrieval in an electric pressure cooker for 3 minutes (total time in pressure cooker, 30 min) in a citrate buffer at pH 6.0. The antibody was applied at a dilution of 1:30 for 32 minutes using the Ventana Nexus autostainer with a basic diaminobenzidine detection kit, endogenous peroxidase blocking, and staining amplification kit.
Appropriate positive and negative controls were used. Reactivity was interpreted as positive or negative. Positive cases were graded according to the percentage of tumor cells with staining, with 1ϩ representing 0 -30% positivity, 2ϩ representing Ͼ30 -70% positivity, and 3ϩ representing Ͼ70% positivity. Cases of positive staining were assessed as to the localization of staining to cytoplasm, nucleus, or both of tumor cells. Diffuse cytoplasmic staining of nontumor cell types was not observed.
FISH Methods for Detection of t(2, 5)(p23;q35) and Other Rearrangements of 2p23 (ALK), using ALK and NPM/ALK Probes on ParaffinEmbedded Tumor Tissue FISH procedures were performed on 4-to 5-m unstained tissue sections using an NPM/ALK twocolor FISH probe specific for the t(2, 5)(p23;q35) and a two-color, break-apart ALK probe that flanks the ALK gene region at 2p23 for detection of the alternative rearrangements involving the ALK gene. The NPM/ALK probes were obtained from Dr. Steve Morris, and the ALK break-apart probe is commercially available (Vysis, Downers Grove, IL). Before the hybridization, the slides were pretreated using the VP2000 automated slide processor (Vysis) using the program specified for paraffin slides. Briefly, the program included deparaffinization of the slides, followed by dehydration, 0.2 N HCL treatment for 15 minutes, and incubation in sodium thiocyanate for 20 minutes at 80°C. The slides were then digested in protease for 15 minutes at 37°C, rinsed, and dehydrated. For FISH, three overlapping chromosome 5 cosmid clones (13, 15-2, and 47C12) located immediately centromeric to the NPM gene locus and an ALK P1 clone, which is homologous to the ALK gene locus translocated in the t(2, 5), were labeled by nick translation with Spectrum Green and Spectrum Orange, respectively, and then purified using the Bio-Spin P-30 chromatography column (Bio-Rad, Hercules, CA). For each hybridization, the labeled probes were combined in equal amounts (50 ng each), lyophilized with 1 g of Cot-1 DNA, and resuspended in LSI Hybridization Buffer (Vysis). For the cases that did not exhibit the t(2, 5), the LSI ALK (Vysis) was used according to manufacturer's instruction. For hybridization, 10 L of the probe mixture was placed on the pretreated tissue section, coverslipped, and sealed. The probe and target DNA were co-denatured at 75°C for 5 minutes, followed by an overnight hybridization at 37°C using the HybRite automated FISH system (Vysis). After hybridization, the slides were washed for 2 minutes in 2ϫ SSC/0.1% NP-40 at 72°C
, followed by 2 minutes in 2ϫ SSC/0.1% NP-40 at room temperature. The slides were counterstained with 4', 6-diamidino-2-phenylindole (DAPI) at a concentration of 125 ng/mL in antifade solution. Analysis was performed on an Olympus BX51 fluorescence microscope equipped with appropriate filters and Cytovision FISH system image capture software (Applied Imaging, Santa Clara, CA). For each case, 100 cells were scored for the presence of the t(2, 5) as evidenced by juxtaposition of the red (ALK) and green (NPM) signal forming a yellow "fusion" signal. The false-positive rate for this FISH system, as established by University of Nebraska Medical Center Human Genetics Laboratories before this study, is 0 -7%, with cutoff at 12%. For the ALK break-apart probe, the cells were scored for a "separation" of the green and red signal, which is indicative of a rearrangement of the ALK gene region. The false-positive rate for this test is 0 -10%, with a cutoff of 15%.
RESULTS
The immunohistochemical findings are summarized in Tables 1 and 2 . Three of 10 IMTs, all from children, showed staining for both ALK1 and p80 ( Fig. 1 , A-C); one IMT showed expression of only p80. The staining pattern in all of these IMTs was distinctly and diffusely cytoplasmic in single welldefined cells. No cytoplasmic or nuclear staining of nontumor cell types was observed. A fibrillary, submembranous, or punctate quality of the cytoplasmic staining in these IMTs was not discernible.
Among the other mesenchymal tumors, no cases of nodular fasciitis, fibromatosis, infantile myofibromatosis, infantile fibrosarcoma, synovial sarcoma, myofibrosarcoma, or leiomyoma showed immunohistochemical reactivity for either ALK1 or p80. Positivity for both ALK1 and p80 was seen in five rhabdomyosarcomas (four alveolar and one embryonal, all from children; Fig. 2 , A-C), two malignant peripheral nerve sheath tumors (both from children), one leiomyosarcoma (from a child), and one malignant fibrous histiocytoma (from an adult). Two additional malignant peripheral nerve sheath tumors (one from an adult, one from a child) showed positivity for only p80. One other embryonal rhabdomyosarcoma (from a child) showed positivity for only ALK1. The staining pattern in all but two non-IMTs was diffusely cytoplasmic. Three alveolar rhabdomyosarcomas displayed a distinctive punctate, dot-like pattern of cytoplasmic staining visible at 40 -100ϫ. With the exception of the dotlike cytoplasmic reactivity in alveolar rhabdomyosarcomas, the cytoplasmic staining for ALK1 and p80 in non-IMTs was less intense than in IMTs. The non-IMTs with 1ϩ positivity displayed a low percentage of reactive cells, Ͻ10% in 6 of 10 cases. In all of the tumors with both ALK1 and p80 staining, the same types of cells were positive with both markers. Among the rhabdomyosarcomas, primitive round or polygonal cells and rhabdomyoblasts with eccentric nuclei and eosinophilic cytoplasm were positive, and in general, the less differentiated cells appeared to stain more frequently.
The FISH results for ALK1-and/or p80-positive tumors are shown in Table 3 . Among the three IMT that could be analyzed, all three had ALK rearrangements with the ALK break-apart probe (two classic splits and one complex variant), and none had an NPM/ALK fusion detected. All of these IMT displayed cytoplasm ALK1 and/or p80 reactivity. Among the six rhabdomyosarcomas that could be analyzed, one each of embryonal and alveolar subtypes were positive for NPM/ALK and displayed diffuse, weak cytoplasmic ALK1 and/or p80 staining. One embryonal rhabdomyosarcoma with weak cytoplasmic ALK1 and p80 reactivity was negative for ALK rearrangements but had three copies of 2p23. Three alveolar rhabdomyosarcomas with dot-like cytoplasmic ALK1 and p80 reactivity had either three to six copies of 2p23 without ALK rearrangements in two cases or had a complex ALK rearrangement with the ALK break-apart probe. One malignant peripheral nerve sheath tumor was positive for NPM/ALK by FISH and was reactive for p80. One case each of leiomyosarcoma and malignant fibrous histiocytoma had two and four copies of 2p23, respectively, but lacked ALK and NPM/ALK rearrangements.
DISCUSSION
IMT is classified with intermediate neoplasms in the current World Health Organization Histological Typing of Soft Tissue Tumors (16) . Recent studies have identified chromosomal abnormalities occurring in a proportion of pulmonary and extrapulmonary IMTs, lending support to the concept of IMT as a neoplasm (3-5, 9, 24 -28) . These recurrent abnormalities involve chromosome 2p21-24, are associated with ALK deregulation, and are characterized by ALK expression by immunohistochemistry (3) (4) (5) . The understanding of the relationship between inflammatory pseudotumor and inflammatory pseudotumor-like neoplasms continues to evolve, although it is clear that both reactive and neoplastic processes have histologic similarities (1, 7, 29 -32) .
Originally described in anaplastic large cell lymphoma, ALK abnormalities identify a distinct subgroup of anaplastic large cell lymphomas with a favorable prognosis. Recent studies have reported the association of ALK expression in IMT with a younger age at presentation (4, 5, 7) . Immunohistochemistry for ALK expression, using both monoclonal and polyclonal antibodies, has previously correlated well with results of reverse transcriptase polymerase chain reaction, FISH, and conventional cytogenetics for detection of ALK abnormalities (3, Previous studies have shown that ALK gene rearrangements and/or ALK expression are found in anaplastic large cell lymphoma, IMT, and cell lines from neuroblastoma, neuroectodermal tumors, malignant melanoma, small cell lung carcinoma, and rhabdomyosarcoma (Table 4) . Non-neoplastic central nervous system tissue also expresses ALK. The present study of IMT and other mesenchymal neoplasms demonstrated ALK1 and/or p80 reactivity in IMTs (40%) and in rhabdomyosarcomas (19%), malignant peripheral nerve sheath tumors (40%), malignant fibrous histiocytomas (9%), and leiomyosarcomas (10%). These findings confirm those of previous studies, which have shown ALK1 immunohistochemical reactivity in 8 -62% of IMTs and "inflammatory pseudotumors" (3, 5, 7-9, 34). The present study also confirmed the presence of ALK and/or p80 expression in rhabdomyosarco- IMT, inflammatory myofibroblastic tumor; ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; MPNST, malignant peripheral nerve sheath tumor; LMS, leiomyosarcoma; MFH, malignant fibrous histiocytoma; NPM, nucleophosmin; FISH, fluorescence in situ hybridization.
a Two IMTs had classic splits, and one had a complex variant with 1-2 fusion and 2 red signals.
b One ARMS had a complex variant split signal with the ALK breakapart probe, which included three fusion and two red signals and a negative NPM/ALK signal. mas, especially the alveolar type, and identified other mesenchymal neoplasms with ALK expression. Correlation of the immunohistochemical findings with FISH probes for ALK and NPM/ALK yielded interesting evidence of ALK rearrangements or extra copies of 2p23 in ALK1-positive non-IMTs. All of three IMTs had either classic ALK split signals or a complex variant fusion signal. The other nine ALK1 and/or p80-reactive mesenchymal tumors analyzed by FISH displayed either extra copies of 2p23 in five cases or ALK rearrangements, with an NPM/ALK fusion in three cases and a variant ALK fusion in one case; one case could not be analyzed. Among the alveolar rhabdomyosarcomas, there was an association between the cytoplasmic dot-like pattern of ALK1 and p80 immunohistochemical staining and extra copies of 2p23. The recent study by Cook and colleagues (8) did not demonstrate ALK expression in nodular fasciitis, desmoids, or gastrointestinal stromal tumors. Lawrence and colleagues (4) reported that ALK was not expressed in nodular fasciitis, inflammatory liposarcoma, inflammatory leiomyosarcoma, or angiomatoid malignant fibrous histiocytoma.
Oncogenesis subsequent to translocations involving the ALK gene occurs as a result of constitutive expression and activation of ALK, with abnormal phosphorylation of cellular substrates. Based on studies of anaplastic large cell lymphoma and IMT, a variety of genes are capable of deregulating ALK. A single fusion partner has not been found in ALK-positive anaplastic large cell lymphomas; rather, a variety of fusion partners has been identified, including NPM, clathrin, nonmuscular tropomyosin (TPM3), or TRK-fused gene (TFG). Previous studies of ALK expression in anaplastic large cell lymphoma have shown recurrent characteristic localization patterns for ALK protein associated with specific ALK fusion proteins (11) (12) (13) . The variant fusions give rise to different ALK immunohistochemical staining patterns than the typical nuclear or nuclear and cytoplasmic staining seen with the t(2, 5)(p23; q35) NPM-ALK fusion protein. The most common pattern of ALK expression seen in the variant translocations is diffuse cytoplasmic staining without a significant nuclear component. The TPM-ALK fusion genes found in IMT and anaplastic large cell lymphoma were associated with intense, predominantly cytoplasmic staining (4, 35) . In addition to identifying the TPM3-ALK and TPM4-ALK fusion genes in IMT, Lawrence and colleagues (4) identified the possibility of at least two alternative ALK fusion mechanisms in IMT, resulting in predominantly cytoplasmic (3 cases) or predominantly nuclear (1 case) localization. ALK1-staining patterns in IMTs have recently been described as diffuse cytoplasmic, granular cytoplasmic, or nuclear membranous, with the diffuse cytoplasmic pattern occurring most frequently (8) . The possibility exists that multiple mechanisms may result in ALK deregulation; for example, point mutations involving the ALK gene could also cause overexpression and abnormal trafficking of ALK between the nucleus and cytoplasm. Whether clear-cut molecular-morphologic correlates will emerge is a question of great interest.
The IMTs in our study showed a diffuse cytoplasmic staining pattern, which was also observed in the ALK-positive malignant peripheral nerve sheath tumors, malignant fibrous histiocytomas, and leiomyosarcomas. Three of the alveolar rhabdomyosarcomas showed a characteristic dot-like pattern of cytoplasmic staining, two of these cases had additional copies of 2p23, and one had a variant ALK fusion. This suggests that not only a specific fusion gene, but also other mechanisms can result in ALK overexpression in neoplasms with a variety of cytogenetic abnormalities. Alveolar rhabdomyosarcoma is often associated with a recurrent translocation involving the FKHR gene on chromosome 13q14 and the PAX3 gene at 2q35 or PAX7 gene on 1p36 (36) . Less is known about the cytogenetic abnormalities in malignant peripheral nerve sheath tumor, malignant fibrous histiocytoma, or leiomyosarcoma. The data from this study suggest that there may be a subset of mesenchymal neoplasms that have in common abnormalities resulting from ALK deregulation and overexpression.
In this study, both the monoclonal antibody for ALK1 and the polyclonal antibody p80 were used to evaluate ALK expression. Overall, the sensitivities of these antibodies was comparable, although p80 detected positive staining in one IMT and two malignant peripheral nerve sheath tumors that were nonreactive with the ALK1 antibody. Conversely, ALK1 detected ALK expression in one case of rhabdomyosarcoma that was nonreactive with the p80 antibody. Overall, the ALK1 antibody staining was easier to interpret, with a cleaner background in comparison to p80, as reported by previous investigators (12, 33) . As in our previous study, the immunohistochemical expression of ALK1 and p80 was strongly associated with structural or numerical abnormalities of the ALK region on chromosome 2p23 (5) .
Although the ALK immunoreactivity and cytogenetic abnormalities in rhabdomyosarcoma, malignant peripheral nerve sheath tumor, leiomyosarcoma, and malignant fibrous histiocytoma are as yet incompletely characterized as to numerical or structural chromosomal abnormalities involving 2p23 or as to ALK deregulation by other means, the findings in this study support the concept of ALK involvement in a larger group of mesenchymal neoplasms, some of which have other known clonal abnormalities. Immunohistochemistry for ALK1 and p80 is useful when positive as an indicator of 2p23 rearrangement in IMT but must be interpreted in the context of histologic and other clinicopathologic data if used as an adjunct for differential diagnosis. Although the frequency of ALK1 immunoreactivity in IMT ranges from 36 -60% (5, 8) , ALK1 and p80 reactivity provide evidence to support the diagnosis of IMT, with the caveats that the typical histologic features are present and that anaplastic large cell lymphoma has been excluded. When negative, careful consideration of alternative diagnoses, including nonneoplastic or inflammatory pseudotumors, is critical, although a significant percentage of IMTs will not exhibit ALK1 and p80 expression. Because a small proportion of various sarcomas in this study demonstrated ALK1 and p80 reactivity, further investigation of the role of ALK deregulation in mesenchymal neoplasms may yield information of potential biologic and therapeutic significance. 'When in the course of human events it becomes necessary' (with an apology to Thomas Jefferson) to come up with a major new textbook of gynecologic pathology, the most important prerequisite is the confluence of minds: that of a firstclass publisher experienced in such matters, and that of team of enthusiastic authors/editors willing to see to it that the project is completed in due time. Preferably, the putative editors should have a respectable track record. In the present case it helped that all three editors have written extensively on gynecologic pathology, and it definitely does not hurt that they have authored chapters for books that could now be considered as a competition of their own. For the record I should mention that many years ago I reviewed Dr. Russell's book on the pathology of the ovaries, which is now in part incorporated in the present book; I still think that it is one of best books of ovarian pathology ever written. This voluminous book is a physically beautiful piece of art reflecting the know-how of both the British publisher and the transcontinental team of editors and contributors. In contrast to other major textbooks of gynecologic pathology, its illustrations are almost all in color and, all other things being equal, that is an enormous advantage-pathology is still in effect a visual discipline. The editors deserve compliments for assembling such a cornucopia of gross and microscopic figures, and the publishers are to be congratulated for rendering them in print so brilliantly.
Book Review
The beauty of the illustrations should, however, not detract one from the well-written and masterfully edited text. By all standards it is comprehensive, informative, and replete with useful data and diagnostic hints. In contrast to the verbosity of some other texts, this one is rather lapidary. For my part, I find it not only more desirable but also more admirable-concise writing requires more effort than semiautomatic dictation of whatever comes to one's mind. The present text strikes the right balance between being comprehensive and being to the point. It is just right for a busy pathologist swamped in his or her daily practice with tons of surgical material. A structured and systematic approach to each entity, applied throughout the book, will make it also attractive to novices who may decide to read it cover to cover over a period of several moths or even years. The tables dealing with the differential diagnosis of closely related or morphologically similar entities are a feature worth mentioning, and one regrets only that the book does not contain more of them. Tabular presentations of immunophenotypes of various tumors are yet another notable attraction. The references are well chosen and up to date.
The review copy of this book reached me 6 months after it appeared in print. One of the possible reasons, as I learned from talking with Dr. Robboy, is that the demand exceeded the initial supply, surpassing the publisher's expectations. From what I know about medical publishing, I would predict that the demand will remain strong, and I predict that many more copies of this wonderful book will be sold over the next few years all over the world.
Ivan Damjanov University of Kansas School of Medicine, Kansas City, Kansas
